Abstract:Background: Epigenetic mechanisms such as 5-methylcytosine (5mC) DNA methylation, histone acetylation and long non-coding RNAs (lncRNAs) are associated with aging processes and cardiovascular disease. Modification of the novel N6-methyladenine (m6A) DNA implicates this epigenetic mark in human malignant disease, but its role in atherosclerosis (AS) is largely unknown.Methods: We used ELISA to determine leukocyte global 5mC and m6A levels in 207 AS patients and 142 sex- and age-matched controls. Gene expression was examined by qRT-qPCR, western blot analysis and immunohistochemistry in mice with AS induced by a western diet, and oxidized low-density lipoprotein (ox-LDL)-treated human umbilical vein endothelial cells (HUVECs) and human monocytic cells (THP-1). Chromatin immunoprecipitation (ChIP) assay and dual-luciferase reporter assay were used to measure the transcriptional regulation of the lncRNA myocardial infarction-associated transcript (MIAT). Linear regression analysis was used to assess predictors of progression of carotid plaque size and carotid intima media thickness (CIMT).Findings: Leukocyte level of m6A but not 5mC was decreased with increased carotid plaque size and CIMT in AS patients. Serum LDL and leukocyte m6A levels were associated with progression of carotid plaque size and CIMT. LDL level and CIMT were also independently related to m6A level. Reduced m6A level was further confirmed in leukocytes and endothelium in WD-induced AS mice and ox-LDL treated HUVECs and THP-1 cells. Decreased m6A level was related to upregulated ALKBH1, the demethylase of m6A. Silencing of ALKBH1 or hypoxia-inducible factor 1α (HIF1α) could rescue the ox-LDL-increased level of MIAT, a hypoxia-response gene. Mechanically, ox-LDL induced HIF1α for transfer into the nucleus. Nuclear HIF1α bound to the ALKBH1-demethylated MIAT promoter and transcriptionally upregulated its expression.Interpretation: Elevated ALKBH1 level in endothelium and leukocytes reduced m6A level, which is associated with plaque progression. The lncRNA MIAT was identified as a novel target of m6A DNA methylation in AS pathogenesis.Funding: This work was supported by the National Natural Science Foundation of China (Grant numbers: 81970257 and 81778272) and the CAMS Innovation Fund for Medical Sciences (Grant numbers: 2017-I2M-3-005).Declaration of Interest: All other authors declared no conflict of interest.Ethical Approval: The protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University in October 2018 (no. L-2018-43). Signed informed consent was obtained from each participant before entering this study.

m6A RNA Methylation Decreases Atherosclerotic Vulnerable Plaque Through Inducing T Cells

Vascular Smooth Muscle FTO Promotes Aortic Dissecting Aneurysms via m6A Modification of Klf5

RNA N 6 -methyladenosine modulates endothelial atherogenic responses to disturbed flow in mice

Alteration of N6-methyladenosine Modi Fi Cation Pro Fi Les in the Neutrophilic RNAs Following Ischemic Stroke

M6A plays a potential role in carotid atherosclerosis by modulating immune cell modification and regulating aging-related genes

N6-Methyladenine DNA Associated with Plaque Progression in Atherosclerosis Via Myocardial Infarction-Associated Transcript

FTO-mediated RNA M6a 6 A Methylation Regulates Synovial Aggression and Inflammation in Rheumatoid Arthritis

N6-methyladenosine Demethylase FTO Impairs Hepatic Ischemia–reperfusion Injury Via Inhibiting Drp1-mediated Mitochondrial Fragmentation

METTL14 Mediated M6a Modification to LncRNA ZFAS1/ RAB22A: A Novel Therapeutic Target for Atherosclerosis

RNA-m6A modification of HDGF mediated by Mettl3 aggravates the progression of atherosclerosis by regulating macrophages polarization via energy metabolism reprogramming

The m6A demethylase fat mass and obesity-associated protein mitigates pyroptosis and inflammation in doxorubicin-induced heart failure via the toll-like receptor 4/NF-κB pathway

FTO-mediated RNA m6A methylation regulates synovial aggression and inflammation in rheumatoid arthritis

Cerebroprotective Role of N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) After Experimental Stroke

N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells

FTO overexpression inhibits apoptosis of hypoxia/reoxygenation-treated myocardial cells by regulating m6A modification of Mhrt

Methyltransferase-like 14 silencing relieves the development of atherosclerosis via m6A modification of p65 mRNA

Fat mass and obesity-associated protein attenuates lipid accumulation in macrophage foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice.

Comprehensive analysis of the m6A demethylase FTO in endothelial dysfunction by MeRIP sequencing

M6a Mrna Methylation Controls Autophagy and Adipogenesis by Targeting Atg5 and Atg7

N6-Methyladenosine Demethylase FTO Controlsmacrophage Homeostasis in Diabetic Vasculopathy

Integrated Analysis of M6a Mrna Methylation in Rats with Monocrotaline-Induced Pulmonary Arterial Hypertension.